Target intelligence / Profile preview

Chorionic gonadotropin subunit beta 1 (CGB1)

Target
CGB1
Molecular classification
Other (hypothetical glycoprotein hormone subunit, not a functional receptor, enzyme, transporter, etc.)
01

Overview

Chorionic gonadotropin subunit beta 1 (CGB1) is one of several highly homologous genes that encode the beta subunit of human chorionic gonadotropin (hCG), a glycoprotein hormone critical for the maintenance of pregnancy[1][2][4][6]. However, the CGB1 gene is atypical within this family: although transcripts from CGB1 have been detected in vivo and shown to associate with polysomes—suggesting potential for translation—a bona fide CGB1 protein product has not been identified or isolated to date[1][2]. Additionally, the hypothetical protein encoded by the canonical CGB1 open reading frame does not share significant similarity with the functional hCG beta subunit, due to a frameshift mutation that alters the protein sequence[1][2]. Only a subset of CGB genes (typically CGB, CGB5, CGB7, CGB8) encode the functional beta subunit of hCG; CGB1 and CGB2 were long considered pseudogenes, and their biological relevance is unclear[2]. Although CGB1 transcript expression has been reported in some cancers, including ovarian cancer, there is little evidence for a biologically active protein or a defined role as a drug target, biomarker, or mediator of disease or normal physiology[4]. CGB1 is not a recognized drug target, receptor, enzyme, transporter, or signaling protein according to current knowledge and major annotation resources[1][6]. It should not be conflated with the functional hCG beta subunit (encoded by CGB, CGB5, etc.), which has established physiological and clinical significance. There is no evidence of drugs interacting with CGB1, nor any mechanism of action, pharmacodynamic biomarkers, or safety concerns specific to this gene or hypothetical protein. Due to the lack of confirmed protein product or physiological function, and historical misclassification as a pseudogene, CGB1 should not be considered a viable or canonical therapeutic target or biomarker[1][2][3].

Other names
Choriogonadotropin subunit beta variant 1chorionic gonadotropin beta subunit 1chorionic gonadotropin, beta polypeptide 1CGB1
02

Disease associations

Other (possible expression in ovarian cancer, relevance unknown)

Beyond the preview

Go deeper on Chorionic gonadotropin subunit beta 1 (CGB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chorionic gonadotropin subunit beta 1 (CGB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call